Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to ...

New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

The FDA pulls back another treatment that doesn't work against omicron, and the federal government warns that without more funding it'll run out of antibodies to give states. Jessica was a writer on ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

In the Nature PastCast series, we delve into the archives to tell the stories behind some of Nature’s biggest papers. This year, Nature celebrates its 150th birthday. To mark this anniversary we’re ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

The trial was halted due to inadequate efficacy, Jay Bradner, M.D., Amgen’s executive vice president of R&D, said during a Nov. 4 call with investors, after an ad hoc analysis requested by an internal ...

President Donald Trump, former New Jersey Gov. Chris Christie and former New York City Mayor Rudy Giuliani all received monoclonal antibodies when they were treated for COVID-19. And despite having ...

The global veterinary monoclonal antibodies market is set to surge, reaching USD 3.06 billion by 2030, up from USD 1.70 ...